Onco Wiki / Regimen

Pembrolizumab monotherapy (NSCLC PD-L1 ≥50%, driver-negative, 1L)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

ComponentsDRUG-PEMBROLIZUMAB
IDREG-PEMBRO-MONO-NSCLC
TypeRegimen
Statuspending_clinical_signoff
DiseasesNone declared
SourcesSRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025

Notes

KEYNOTE-024: pembro mono superior to platinum-doublet chemo in PD-L1≥50% driver-negative metastatic NSCLC (5-year OS ~32% vs 16%).

Used By

Handbook Chapters

Indication